Evidence map›Paper›PMID 31464325›Full record

ArticleLab on a chip2019

Synchronized stimulation and continuous insulin sensing in a microfluidic human Islet on a Chip designed for scalable manufacturing.

Aaron L Glieberman, Benjamin D Pope, John F Zimmerman, Qihan Liu, John P Ferrier, Jennifer H R Kenty, Adrian M Schrell, Nikita Mukhitov, Kevin L Shores, Adrian Buganza Tepole and 3 more

Open access · greenAbstract read
In one paragraph

Article in Lab on a chip, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
12.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 112 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Aaron L GliebermanDisease Biophysics Group, Wyss Institute for Biologically Inspired Engineering, Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Pierce Hall, 29 Oxford Street, Cambridge, MA 02138, USA. kkparker@seas.harvard.edu.
Benjamin D Pope
John F Zimmerman
Qihan Liu
John P Ferrier
Jennifer H R Kenty
Adrian M Schrell
Nikita Mukhitov
Kevin L Shores
Adrian Buganza Tepole
Douglas A Melton
Michael G Roper
Kevin Kit Parker
Harvard University · USFlorida State University · USHarvard Stem Cell Institute · US

Funding

Production of clinical-grade diabetes patient-specific induced pluripotent stem cell lines intended for autologous beta cell replacement therapyUC4DK104165 · NIDDK · HARVARD UNIVERSITY · PI MELTON, DOUGLAS A · 2014 to 2017
$7.3M
Microfluidic Devices to Determine Roles of Islet-Secreted LeptinR01DK080714 · NIDDK · FLORIDA STATE UNIVERSITY · PI ROPER, MICHAEL GABRIEL · 2008 to 2025
$5.5M
Modular monitoring of hormone release from human isletsUC4DK116283 · NIDDK · FLORIDA STATE UNIVERSITY · PI HUGHES, CHRISTOPHER C. W., ROPER, MICHAEL GABRIEL · 2017 to 2017
$2.0M
NIDDK NIH HHS R01 DK080714NIDDK NIH HHS UC4 DK104165NIDDK NIH HHS UC4 DK116283
6 · The paper itself

Abstract

Pancreatic β cell function is compromised in diabetes and is typically assessed by measuring insulin secretion during glucose stimulation. Traditionally, measurement of glucose-stimulated insulin secretion involves manual liquid handling, heterogeneous stimulus delivery, and enzyme-linked immunosorbent assays that require large numbers of islets and processing time. Though microfluidic devices have been developed to address some of these limitations, traditional methods for islet testing remain the most common due to the learning curve for adopting microfluidic devices and the incompatibility of most device materials with large-scale manufacturing. We designed and built a thermoplastic, microfluidic-based Islet on a Chip compatible with commercial fabrication methods, that automates islet loading, stimulation, and insulin sensing. Inspired by the perfusion of native islets by designated arterioles and capillaries, the chip delivers synchronized glucose pulses to islets positioned in parallel channels. By flowing suspensions of human cadaveric islets onto the chip, we confirmed automatic capture of islets. Fluorescent glucose tracking demonstrated that stimulus delivery was synchronized within a two-minute window independent of the presence or size of captured islets. Insulin secretion was continuously sensed by an automated, on-chip immunoassay and quantified by fluorescence anisotropy. By integrating scalable manufacturing materials, on-line, continuous insulin measurement, and precise spatiotemporal stimulation into an easy-to-use design, the Islet on a Chip should accelerate efforts to study and develop effective treatments for diabetes.

Indexed as

Lab-On-A-Chip DevicesMicrofluidic Analytical TechniquesElectric StimulationEquipment DesignHumansInsulinIslets of LangerhansInsulin

Identifiers

PMID31464325
PMCPMC6814249
OpenAlexW2971191203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.